Low frequency variants can predetermine antiviral drug resistance development in herpes simplex virus type 1
PLOS Pathogens · 08.06.2026 · 22 (6) · e1014296
DOI: 10.1371/journal.ppat.1014296 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 08.06.2026. Verfasst von Lena Jaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Institute of Virology, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Herpesvirus 1, Human, Drug Resistance, Viral, Antiviral Agents, Acyclovir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Freiburg University Medical Center.
Abstract (Originalsprache)
Severe HSV-1 disease is treated with potent antiviral drugs, in particular aciclovir (ACV) and its derivatives. However, long-term drug exposure in immunocompromised patients can lead to the emergence of ACV-resistant HSV-1 strains and clinical treatment failure. To understand how phenotypic resistances develop on a genomic level, we analyzed the influence of ACV selection pressure on the viral genome of different HSV-1 virus strains in vitro . Growth kinetics and IC 50 determination showed ACV resistance development within a single passage. Next, we performed ultra-deep, non-targeted full-genome Illumina sequencing of the parental and ACV-adapted HSV-1 strains. Interestingly, resistance-conferring mutations rapidly arose in the viral genes UL23 and UL30 and were already present in the parental ACV-naïve strains at extremely low variant frequencies. Based on these findings, we hypothesized that low- frequency mutations develop during continued viral replication. To test this hypothesis, a primary rescued recombinant K17 + strain was repeatedly passaged. Continued passaging indeed increased the proportion of a subset of minor variants and allowed resistance development after, but not before, 10 consecutive passages. In summary, we show that minor variants can facilitate adaptation of HSV-1 populations to selective pressures such as pharmacological inhibition of replication. These findings highlight that deep sequencing might allow early detection of resistance mutations potentially supporting antiviral drug stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Institute of Virology, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.
- Section Clinical Virus Genomics, Institute of Virology, University Medical Center Freiburg, Freiburg, Germany.
- German Consulting Laboratory for HSV and VZV, and Medical Center- Faculty of Medicine, University of Freiburg, Freiburg, Germany.
ORCID-Profile: Jonas Fuchs
Förderung
- Bundesministerium für Bildung und Forschung
- Freiburg University Medical Center
Zitieren
APA
Jaki, L., Full, F., Gieraths, U., Falcone, V., Ruzsics, Z., Hengel, H., Panning, M., & Fuchs, J. (2026). Low frequency variants can predetermine antiviral drug resistance development in herpes simplex virus type 1. PLOS Pathogens, 22(6), e1014296. https://doi.org/10.1371/journal.ppat.1014296
Vancouver
Jaki L, Full F, Gieraths U, Falcone V, Ruzsics Z, Hengel H, et al. Low frequency variants can predetermine antiviral drug resistance development in herpes simplex virus type 1. PLOS Pathogens. 2026;22(6):e1014296. doi:10.1371/journal.ppat.1014296
BibTeX
@article{Jaki2026,
author = {Jaki, Lena and Full, Florian and Gieraths, Udo and Falcone, Valeria and Ruzsics, Zsolt and Hengel, Hartmut and Panning, Marcus and Fuchs, Jonas},
title = {Low frequency variants can predetermine antiviral drug resistance development in herpes simplex virus type 1},
journal = {PLOS Pathogens},
year = {2026},
volume = {22},
number = {6},
pages = {e1014296},
doi = {10.1371/journal.ppat.1014296}
}
EUVIMED